As of 2024-12-13, the EV/EBITDA ratio of Oramed Pharmaceuticals Inc (ORMP) is -4.54. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ORMP's latest enterprise value is 58.27 mil USD. ORMP's TTM EBITDA according to its financial statements is -12.85 mil USD. Dividing these 2 quantities gives us the above ORMP EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.5x - 10.0x | 8.6x |
| Forward P/E multiples | 13.1x - 19.1x | 16.2x |
| Fair Price | (3.12) - (2.13) | (2.91) |
| Upside | -225.2% - -185.5% | -217.1% |
| Date | EV/EBITDA |
| 2024-12-11 | -4.44 |
| 2024-12-10 | -4.60 |
| 2024-12-09 | -4.63 |
| 2024-12-06 | -4.25 |
| 2024-12-05 | -4.60 |
| 2024-12-04 | -4.63 |
| 2024-12-03 | -4.44 |
| 2024-12-02 | -4.46 |
| 2024-11-29 | -4.16 |
| 2024-11-27 | -4.16 |
| 2024-11-26 | -4.16 |
| 2024-11-25 | -4.10 |
| 2024-11-22 | -4.07 |
| 2024-11-21 | -3.97 |
| 2024-11-20 | -3.81 |
| 2024-11-19 | -3.94 |
| 2024-11-18 | -3.53 |
| 2024-11-15 | -3.72 |
| 2024-11-14 | -4.05 |
| 2024-11-13 | -4.00 |
| 2024-11-12 | -4.07 |
| 2024-11-11 | -4.00 |
| 2024-11-08 | -3.97 |
| 2024-11-07 | -4.19 |
| 2024-11-06 | -4.07 |
| 2024-11-05 | -4.10 |
| 2024-11-04 | -4.22 |
| 2024-11-01 | -4.00 |
| 2024-10-31 | -4.19 |
| 2024-10-30 | -4.29 |
| 2024-10-29 | -3.91 |
| 2024-10-28 | -4.00 |
| 2024-10-25 | -4.14 |
| 2024-10-24 | -4.13 |
| 2024-10-23 | -4.19 |
| 2024-10-22 | -4.16 |
| 2024-10-21 | -4.08 |
| 2024-10-18 | -3.99 |
| 2024-10-17 | -4.25 |
| 2024-10-16 | -4.35 |
| 2024-10-15 | -4.10 |
| 2024-10-14 | -4.19 |
| 2024-10-11 | -4.19 |
| 2024-10-10 | -4.18 |
| 2024-10-09 | -4.25 |
| 2024-10-08 | -4.03 |
| 2024-10-07 | -4.29 |
| 2024-10-04 | -4.10 |
| 2024-10-03 | -4.29 |
| 2024-10-02 | -4.22 |